Back to UBS Group AG UBS Group AG

NVAXNVAX

Showing 8 of 29 quarters

Position history for UBS Group AGUBS Group AG's holdings in Novavax, Inc.

Yes. UBS Group holds 1,869,659 shares of NVAX (Novavax), worth $17.6M, as of its Q2 2026 13F filing. It reduced the position by 2,608,042 shares (-58.3%) from Q1 2026. UBS Group has held NVAX in every 13F on record since Q2 2019, 29 quarterly filings.

Current Value

$17.6M

Current Shares

1.9M

Total Value Change

+$11M

Total Shares Change

+1.3M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
1.9M
-58.3%
$17.6M0.0%$9.42
0
2026-Q1
Decreased
4.5M
-8.5%
$36.4M0.0%$8.14
0
2025-Q4
Increased
4.9M
+39.2%
$32.9M0.0%$6.72
38
2025-Q3
Increased
3.5M
+55.9%
$30.5M0.0%$8.67
41
2025-Q2
Increased
2.3M
+60.0%
$14.2M0.0%$6.30
40
2025-Q1
Decreased
1.4M
-70.9%
$9M0.0%$6.41
0
2024-Q4
Increased
4.9M
+823.5%
$39M0.0%$8.04
47
2024-Q3
Increased
525,354
+41.3%
$6.6M0.0%$12.63
36

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used